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Background: Many studies have shown that the prevalence of smoking in schizophrenia is higher than in the
general population. Biological, psychological and social factors influence smoking in patients with schizophrenia.
Methods: The study was carried out in psychiatry outpatient clinics in a tertiary care hospital in Sri Lanka. Every third
patient was selected using systematic sampling from patients diagnosed with schizophrenia according to ICD-10 clinical
criteria. Smoking behaviours were assessed using self-reports. Severity of illness was assessed using Brief Psychiatric
Rating Scale (BPRS). Fagerstrom Test for Nicotine Dependence assessed level of dependence. Readiness to Change
Questionnaire assessed motivation to change smoking behaviour.
Results: The sample consisted of 306 patients with schizophrenia. Mean age was 38.93 years (SD 10.98). There
were 148 males (48.4%). Mean duration of illness was 12.63 years (SD 8.38). Current medication was oral atypical
antipsychotics 103, clozapine 136, oral typicals 29 and depot typicals 38. Prevalence of tobacco use among males
was 30.41% (95% CI 22.91 to 37.90) and among females 1.90% (95% CI −0.25 to 4.05). Prevalence of current
smoking among males was 20.27% (95% CI 13.72 to 26.82). None of the females smoked. Prevalence of smokeless
tobacco use among males was 10.14 (95% CI 5.22 to 15.05) and among females 1.90 (95% CI −0.03 to 4.05). When
patients treated with clozapine were excluded from the analysis, prevalence of tobacco use was 41.6% among
males and 3.2% among females and prevalence of smoking was 29.9% among males. Prevalence of tobacco use
was lowest in patients treated with clozapine 18.31 (95% CI 9.09 to 27.53) and highest in those treated with depot
antipsychotics 47.83 (95% CI 25.74 to 69.91).
Conclusions: Prevalence of smoking was less than in many countries. This is influenced by prevalence in the general
population and low affordability. Risk of tobacco use was significantly less among patients treated with clozapine.Background
A recent report by the Royal College of Physicians and
the Royal College of Psychiatrists in the UK highlights
the problem of smoking among the mentally ill [1]. Many
studies have shown that the prevalence of smoking in
schizophrenia is higher than in the general population
[2-6]. Smoking has health implications for patients with
schizophrenia because it increases the risk of cardiovascular
disease and malignancies and causes overall poor physical
health and premature death. Smoking in patients with* Correspondence: varunidesilva2@yahoo.co.uk
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article, unless otherwise stated.mental illness is also important because it increases the
metabolism of medication through induction of the liver
cytochrome P450 enzymes. It is necessary to identify
factors which increase risk of smoking in mental illness,
in order to implement preventive measures in this popula-
tion [7].
A meta-analysis of prevalence of smoking in patients
with schizophrenia, in different cultures, shows strong
association between schizophrenia and current smoking
(weighted average odds ratio, OR = 5.9) [8]. The prevalence
of smoking in different countries ranges from 14% to 88%,
with majority reporting prevalence between 40% and 70%.
Biological, psychological and social factors influence
smoking in patients with schizophrenia. There is evidence
of increased genetic vulnerability [9]. The dorsal anteriorntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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increased risk of smoking co-morbidity in schizophre-
nia [10].
It has been suggested that nicotine may be used as self-
medication for psychotic symptoms of schizophrenia [11].
However, smokers have higher Brief Psychiatric Rating
Scale (BPRS) scores and experience more hospitalizations
[12]. Nicotine may compensate for cognitive deficits in
schizophrenia by improving cognitive functions such as
attention and vigilance, spatial organization and visuospatial
memory [13-17]. Nicotine increases midbrain dopaminergic
activity, which may reduce negative symptoms in schizo-
phrenia and activate a reward system [18,19]. Smoking
may also be perceived as alleviating anxiety and mood
symptoms by those who are dependent because it relieves
unpleasant withdrawal symptoms [20]. A study of motiva-
tors for smoking in schizophrenia found that sedation and
anxiety reduction, enhancement of pleasurable feelings and
relaxation, craving, habit, sociability and increased need
of energy or stimulation were described as motivators
for smoking [21].
Risk of smoking in schizophrenia may depend on the
type of antipsychotic. Typical antipsychotics such as halo-
peridol are associated with an increased risk of smoking.
This may be explained by the increase of dopaminergic
activity by nicotine, which compensates for the D2 block-
ade produced by antipsychotics [17,22]. However, the
degree of dopamine blockade by typical antipsychotics
varies widely.
Several studies have reported that clozapine reduces
smoking in patients with schizophrenia [23-25]. When 12
patients treated with haloperidol were switched to cloza-
pine, they reduced the number of cigarettes smoked [24].
Another study among outpatients found that there was a
significant decrease in daily cigarette use after clozapine
treatment, as compared to treatment with typical neuro-
leptics. The decrease was confined to heavy smokers [25].
Clozapine has also been found to decrease alcohol use
among patients with schizophrenia [23]. The unique mech-
anism of action of clozapine may be responsible for the
reduced risk of substance use in patients with schizo-
phrenia. Clozapine binds more strongly to D4 dopamine
receptors than to D2 receptors, and it is also more effect-
ive than other antipsychotics in treating cognitive deficits
in schizophrenia [26]. It has also been hypothesized that
clozapine may reduce craving.
Although there is evidence that antipsychotics influence
rates of smoking in patients with schizophrenia, the
evidence is based on small intervention studies. This study
had two main objectives. One was to identify the preva-
lence of smoking among patients with schizophrenia in a
country with low overall prevalence of smoking. The other
objective was to identify the association between smoking
and antipsychotic treatment.Methods
This cross-sectional study was carried out in the psych-
iatry outpatient clinics (including a specialized clozapine
clinic) in a tertiary care hospital in Sri Lanka. Sri Lanka is
a middle-income country with a low prevalence of smok-
ing among the general population. Among males in the
general population, prevalence of smoking was 29.9% in
urban areas and 24.4% in rural areas [27,28]. Smoking is
rare among females.
Sample size was calculated to detect 40% prevalence
with a precision of 0.6. The study population was patients
registered in the outpatient clinics of the unit, with a
diagnosis of schizophrenia according to ICD-10 clinical
criteria. Every third patient was selected using systematic
sampling.
Smoking behaviours were assessed using self-reports.
Wherever possible, this information was cross checked
with accompanying family members. Current tobacco use
was defined as smoking cigarettes or beedi (traditional
Indian cigarettes) or use of smokeless tobacco (tobacco
used in betel quid). Current tobacco use and current
smoking were defined as use within the last 30 days.
Severity of illness was assessed using BPRS. Fagerstrom
Test for Nicotine Dependence assessed level of dependence.
Readiness to Change Questionnaire assessed motivation
to change smoking behaviour [29].
Written informed consent was obtained from all patients
who participated in the study. Ethical clearance was
obtained from the Ethics Review Committee of the Na-
tional Hospital of Sri Lanka. Data analysis was carried
out using SPSS-14 computer software. Chi-square tests
assessed association between categorical variables. One-way
ANOVA and independent t tests assessed difference be-
tween means.
Results
Description of the sample
The sample consisted of 306 patients. Mean age was 38.93
years (SD 10.98). There were 148 males (48.4%). Mean
duration of illness was 12.63 years (SD 8.38). Current
medication was risperidone 74 (24.2%), olanzapine 50
(16.3%), trifluoperazine 32 (10.5%), haloperidol 6 (1.9%),
chlorpromazine 14 (4.6%), clozapine 136 (44.4%) and depot
fluphenazine 41 (13.4%). Eight patients on either risperi-
done or olanzapine were also treated with an oral typical
antipsychotic. Polypharmacy was commonest among pa-
tients treated with a depot antipsychotic with 8 (19.5%)
also treated with risperidone or olanzapine and 10 (24.4%)
treated with an oral typical antipsychotic. Eleven patients
(8.08%) on clozapine were also prescribed another atypical
antipsychotic, while concomitant trifluoperazine use was
recorded in two (0.65%). Mood stabilizers were prescribed
in 13 (4.25%). Patients who were on clozapine were refrac-
tory to treatment with at least two other antipsychotics.
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Prevalence of current tobacco use (smoking and smokeless
tobacco use) was 15.69% (95% CI 11.59 to 19.78). Preva-
lence of tobacco use among males was 30.41% (95% CI
22.91 to 37.90) and among females 1.90% (95% CI −0.25 to
4.05). Prevalence of current smoking among males was
20.27% (95% CI 13.72 to 26.82). None of the females
smoked. Prevalence of smokeless tobacco use among males
was 10.14% (95% CI 5.22 to 15.05) and among females
1.90% (95% CI −0.03 to 4.05). The mean number of ciga-
rettes or beedis smoked daily was 8.81 (SD = 2.91).
When patients treated with clozapine were excluded
from the analysis, prevalence of tobacco use increased to
41.6% among males and 3.2% among females and the
prevalence of smoking among males was 29.9%.
Table 1 compares characteristics of tobacco users and
non-users. Although mean duration of illness was longer in
tobacco users, the difference was not significant (t = 0.75,
p = 0.42). There was no significant difference in mean BPRS
score between tobacco users 32.06 (SD 9.17) and non-users
32.12 (SD 9.02) (t = 0.38, p = 0.97). There was no significant
difference in BMI between tobacco users 22.17 (SD 3.22)
and non-users 23.76 (SD 4.11) (t = 2.53, p = 0.12).
Dependence was assessed using the Fagerstrom Test for
Nicotine Dependence. Among current smokers, 23 (76.6%)
had low-moderate dependence and 7 (23.3%) high de-
pendence. Among smokeless tobacco users, 13 (72.2%)
had low-moderate dependence and 5 (27.7%) high de-
pendence. There was no significant difference in the
level of dependence among smokers and smokeless to-
bacco users (χ2 = 0.13, df = 2, p = 0.94). Among tobacco
users, 43 (89.5%) were daily users. Among smokers, 14
(46.6%) smoked ≤5 cigarettes/day. All those who were
highly dependent smoked ≥10 cigarettes/day.
Readiness to Change Questionnaire assessed the mo-
tivation to change. Of the tobacco users, 19 (41.3%) were
in the pre-contemplation stage, 12 (26.1%) were in the
contemplation stage and 15 (32.6%) in the action stage.
Antipsychotics and tobacco use
Because none of the females smoked and prevalence of
smokeless tobacco use was also low among females, weTable 1 Comparison of tobacco users and non-users
Tobacco users Non-users Significance
Age in years,
mean (SD)
41.56 (10.58) 38.44 (11.01) t = 1.82, p = 0.07
Gender males (%) 93.8 39.9 χ2 = 46.95, p = 0.001
Duration of illness,
mean (SD)
13.54 (9.27) 12.47 (8.21) t = 0.81, p = 0.42
BPRS, mean (SD) 31.84 (8.99) 32.09 (8.81) t = 0.16, p = 0.88
Body mass index,
mean (SD)
22.17 (3.22) 23.77 (4.11) t = 2.53, p = 0.63included only males in the analysis of the relationship
between tobacco use and antipsychotics. Table 2 shows
that prevalence of tobacco use was lowest in patients
treated with clozapine 18.31 (95% CI 9.09 to 27.53) and
highest in those treated with depot antipsychotics 47.83
(95% CI 25.74 to 69.91). Logistic regression analysis shows
that among males, risk of tobacco use was significantly
lower in patients treated with clozapine [OR 0.36 (95% CI
0.16 to 0.84)]. This is despite the fact that patients
treated with clozapine had higher BPRS mean scores
34.57 (SD11.28) than those on atypical antipsychotics 30.46
(SD 5.63) or depot antipsychotics 29.30 (SD 4.96).
There was significant difference in mean age (F = 25.16,
p < 0.001), duration of illness (F = 10.85, p < 0.001) and
mean BPRS scores (F = 4.20, p < 0.001) between different
antipsychotic groups. Patients on oral and depot typical
antipsychotics tended to be older and had had longer dur-
ation of illness than those on atypical antipsychotics.
Discussion
We found that the prevalence of tobacco use among males
treated with clozapine was half that of patients on other
antipsychotics. This finding is of importance because the
sample included a large number of patients on clozapine,
whereas previous evidence is mostly based on intervention
studies with small samples [23-25]. The highest preva-
lence of tobacco use among males was in the depot anti-
psychotic group.
The exact mechanism by which clozapine reduces
smoking is not very clear. Clozapine may reduce smoking
through its specific action of reducing cognitive deficits.
Another possibility is that the improved therapeutic re-
sponse to clozapine also reduces risk of smoking. A group
of treatment refractory patients on haloperidol after treat-
ment with therapeutic doses of clozapine showed lower
BPRS scores and reduced the number of cigarettes smoked
[24]. However, our findings do not support this because
the patients on clozapine had higher mean BPRS scores
than those on other antipsychotics.
There is also evidence from a few other studies that
the type of antipsychotic influences the smoking rate.
A study of 39 inpatients with schizophrenia spectrum
disorder found that patients on typical antipsychotics
had the highest prevalence and those on clozapine the
lowest [25,30]. Typical antipsychotics are probably less
effective than clozapine in correcting abnormal sensory
processing and cognitive impairment associated with
schizophrenia. Typical antipsychotics are more likely to
cause extrapyramidal symptoms (EPS), and nicotine may
reduce neuroleptic induced EPS [31,32].
Although many biological mechanisms have been pro-
posed to explain the increased prevalence of smoking in
schizophrenia, our study suggests that sociocultural factors
are also important [8]. This study was conducted in a






antipsychotics n = 29
Depot typical
antipsychotics n = 38
Age years (SD) 39.25 (11.47) 34.54 47.69 47.05
Gender males (%) 45.6 52.2 24.1 60.5
Illness duration years in males (SD) 11.75 (8.81) 12.17 (6.63) 18.42 (8.22) 19.83 (8.0)
BPRS mean in males (SD) 31.87 (6.07) 34.33 (11.67) 28.67 (7.87) 28.88 (4.57)
Prevalence of tobacco use among
males (95% CI)
38.30 (23.87 to 52.72) 18.31 (9.09 to 27.53) 42.86 (−6.58 to 92.29) 47.83 (25.74 to 69.91)
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general population is not high [27,28,33]. The prevalence
of smoking in our study was lower than that reported in
most other countries. When patients treated with clozapine
were excluded, prevalence of tobacco use among males was
41.6% and the prevalence of smoking was 29.9%. This is
similar to the prevalence of smoking among the general
population of 29.9% [27,28].
Social factors can explain the relatively low prevalence
of smoking in our study. In low- and middle-income
countries, affordability significantly influences smoking
rates [34]. A study from India reported that lack of
economic independence and restrictions imposed by
the family appeared to be crucial factors that controlled
the prevalence of smoking among patients with schizo-
phrenia [34]. In Sri Lanka, patients with schizophrenia
do not receive a disability allowance [35]. Most of the
unemployed patients are dependent on their families.
Therefore, they may not be able to afford to purchase
cigarettes. A previous study of outpatients in the same
unit treated with clozapine shows that 55.6% of the
males were unemployed [36]. Another study of patients
with schizophrenia attending follow-up clinics showed
that 42.9% of males reported a monthly income of less
than 150 US$ [35]. Low affordability is supported by
the fact that 10.1% of males used smokeless tobacco in
the form of betel quid, which is cheaper than ciga-
rettes. This is much higher than the prevalence of 1.7%
reported among the general population in urban areas
[37]. Betel quid contains betel leaf (Piper betle), areca-
nut (Areca catechu) slaked lime (calcium hydroxide)
and tobacco [38]. Influence of cultural factors is also
apparent because females in our sample did not smoke
at all which is similar to the pattern in the general
population [39].
Also, in high-income countries, social factors influence
prevalence of smoking among the mentally ill. In these
countries, cigarettes are more affordable to people with
mental illness and smoking is also engrained in the culture
of many institutions that care or provide for the mentally
ill [1]. Many inpatient psychiatry units do not enforce
smoke-free policies, and smoking may facilitate social
interactions.Several limitations must be considered in interpreting
the findings of this study. This study used self-reports of
tobacco use and smoking as in most epidemiological
studies. Previous research has shown that information
obtained from patients and informants underestimates
substance use when compared to laboratory analysis
[40,41]. Only data from males were used in the analysis
of association between tobacco use and antipsychotics.
Conclusions
This study identified two factors which influence tobacco
use in schizophrenia. We found that clozapine is associated
with reduced risk of smoking. The study also found that
social factors significantly affect smoking rates in patients
with schizophrenia. In a society with low smoking rate,
the patients may not have been smokers to start; however,
we do not have evidence to support this. We did not find
an association between smoking and severity of illness
although other studies have found such an association.
Policy makers should explore the possibility of restricting
availability of cigarettes and adopting smoke-free policies
in mental health units.
More research is needed to understand the relationship
between antipsychotics and smoking in patients with
schizophrenia. If other studies are able to replicate the
finding of lower risk of smoking with clozapine, it could
lead to a recommendation to consider clozapine as a treat-
ment option for smokers with schizophrenia.
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